

L-CARnitine in the palliative treatment of advanced PANcreatic cancer (CARPAN)

Submission date 24/03/2011	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 12/04/2011	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 17/05/2011	Condition category Cancer	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Markus Lerch

Contact details
Department of Medicine A
University Medicine Greifswald
Friedrich Löffler Straße 23a
Greifswald
Germany
17475

Additional identifiers

Study information

Scientific Title
L-Carnitine in the palliative treatment of advanced pancreatic cancer (CARPAN): a prospective, randomised, placebo controlled, double blinded, multicentre trial

Acronym
CARPAN

Study objectives

The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, International Union Against Cancer Classification (UICC) Stage IV .

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Commission for the Medical Faculty of the University of Greifswald approved on 30.11.2005, ref no: UV 73/05

Primary study design

Interventional

Study design

Placebo controlled double blinded randomised prospective multicentre study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Advanced pancreatic cancer

Interventions

Intervention (Verum): L-Carnitine 4 g/day

Placebo: Tartaric acid

Both administered orally

The trial duration was 3 month, patient visit at time of enrolment, week 6 and week 12

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

L-Carnitine

Primary outcome(s)

Influence of L-Carnitine on proinflammatory cytokine tumor necrosis factor (TNF)-alpha

Key secondary outcome(s)

1. Influence of L-Carnitine on

1.1. Other proinflammatory cytokines (IL 6, IL8, IL12)

1.2. C-reactive protein (CRP)

1.3. Malnutrition and cancer cachexia, cancer related fatigue syndrome

1.4. Mortality

1.5. Hospital stay

Completion date

31/10/2009

Eligibility

Key inclusion criteria

1. Advanced pancreatic cancer (UICC Stage IV)
2. A Karnofsky Index larger than 60
3. Compliance
4. The consent to participate in the study

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Patients were excluded with a Child-Pugh classification of liver failure greater than Class B
2. A known second malignant tumor
3. Oral or parenteral supplementation with omega-3-fatty acids
4. Treatment with Thalidomide or Infliximab
5. Mental or physical disorders

Date of first enrolment

01/06/2006

Date of final enrolment

31/10/2009

Locations

Countries of recruitment

Germany

Study participating centre

Department of Medicine A

Greifswald

Germany

17475

Sponsor information

Organisation

University Medicine Greifswald (Germany)

ROR

<https://ror.org/00r1edq15>

Funder(s)

Funder type

University/education

Funder Name

University Medicine Greifswald (Germany) - Department of Medicine A

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration